Hartland, 

As part of the four DSMB interim analyses, they would have been able to look at the unblinded data to determine if apabetalone is causing increased MACE, death from any cause or any other adverse events or side effects relative to placebo. Since BETonMACE has passed these four DSMB checks with flying colors, it is safe to assume, in my opinion, that apabetalone is not causing increased MACE, death from any cause, or any other serious adverse events or side effects relative to the placebo group so far in the trial.

However, just because apabetalone isn't increasing MACE doesn't mean that it is having an effect to decrease MACE. There may be no effect of apabetalone on MACE, or apabetalone may be lowering MACE. But in either case it is extremely unlikely that all of the MACE events are occurring only in the placebo group, as some may have interpreted your post as suggesting. 

I hope that helps. 

BearDownAZ